Merck Gets FDA Breakthrough Therapy Designation for MK-6482
July 29 2020 - 9:35AM
Dow Jones News
By Michael Dabaie
Merck & Co. Inc. said the U.S. Food and Drug Administration
granted Breakthrough Therapy designation to MK-6482 for certain
patients with von Hippel-Lindau disease-associated renal cell
Carcinoma.
The FDA also granted orphan drug designation to MK-6482 for VHL
disease. These designations are based on data from a Phase 2 trial
evaluating MK-6482 in patients with VHL-associated clear cell
RCC.
Von Hippel-Lindau disease is a rare genetic disease. Patients
with VHL disease are at risk for benign blood vessel tumors as well
as several cancers, including RCC, Merck said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 29, 2020 09:20 ET (13:20 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024